Protara Therapeutics, Inc. TARA 深 滬
等待開盤 08-10 09:30:00 美东时间
4.12
+0.020
+0.49%
華盛通- 最 高4.175
- 今 開4.13
- 成交量 34.07万股
- 最 低 4.005
- 昨 收 4.10
- 總市值 2.32亿
- 52周最高 7.82
- 市盈率 靜 --
- 換手率 0.61%
- 52周最低 2.97
- 委 比 -96.03%
- 總股本 5620.42万
- 歷史最高 800.00
- 量 比 0.96
- 振 幅 4.15%
- 歷史最低 1.04
- 每 手 1
- 風險率 1.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals reported progress in its oncology and obesity pipeline, obtaining FDA clearance for the registrational study of CRB-701 in oropharyngeal cancer and completing the last patient visit in the CANYON-1 trial of CRB-913 for obesity. The company also appointed new leadership to strengthen its team. Financially, Corbus reported a net loss of $35 million for the second quarter, with $117.9 million in cash on hand.
08-06 12:00
Corbus Pharmaceuticals appoints Leonardo Viana Nicacio as Chief Medical Officer
Corbus Pharmaceuticals Holdings (CRBP) announced the appointment of Leonardo Viana Nicacio as Chief Medical Officer. Nicacio brings over 20 years of pharmaceutical and oncology experience, notably ser...
07-06 20:14
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
Corbus Pharmaceuticals appoints Dr. Leonardo Viana Nicacio as Chief Medical Officer, bringing extensive experience in solid tumor drug development, including ADCs like TIVDAK® for metastatic cervical cancer. The company is set to initiate the TEMPO-1 registrational study for CRB-701 in 2L oropharyngeal squamous cell carcinoma (OPSCC) this summer. Dr. Nicacio emphasizes advancing CRB-701 and CRB-913 to address unmet needs in oncology and obesity, ...
07-06 12:00
Protara Therapeutics Announces Key Medical Leadership Transition
Protara Therapeutics ( ($TARA) ) has issued an announcement. On June 26, 2026, ...
06-30 05:30
Protara Therapeutics Stockholders Approve Governance and Share Increases
Protara Therapeutics ( ($TARA) ) just unveiled an announcement. Protara Therape...
06-16 05:06
Protara Therapeutics Enters $100M At-the-Market Equity Sales Agreement With TD Cowen
$100,000,000Common StockWe have entered into a sales agreement with TD Securities (USA) LLC, or TD Cowen, dated May 13, 2026, or the Sales Agreement, relating to the sale of shares of our common stock, par value $0.001
05-29 05:20
美股大行评级 | Cava、CrowdStrike、Keysight获多家大行上调目标价；家得宝绩后遭多家大行下调目标价
今日重点评级关注：Oppenheimer：维持Protara Therapeutics"跑赢大市"评级，目标价从25美元升至28美元；Piper Sandler：维持Bright Minds Biosciences"超配"评级，目标价从190美元升至220美元
05-21 12:05
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study
Protara reports updated Phase 2 data showing durable responses and favorable safety for TARA-002 in bladder cancer patients.
05-15 23:36
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
JP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26
JP Morgan analyst Brian Cheng maintains Protara Therapeutics (NASDAQ:TARA) with a Overweight and lowers the price target from $27 to $26.
05-15 02:19
